Anti-Glial Fibrillary Acid Protein (GFAP) Purified
RUO: For Research Use Only
Immunoblotting of reduced mouse brain lysate with 5 µg/mL of Anti-GFAP Purified antibody. Bands were visualized using Anti-Mouse IgG HRP (left). Immunocytochemistry of fixed and permeabilized C6 cells using 1 μg/ml of Mouse IgG1 Isotype Control Purified (cat. 14-4714)(center) or Anti-GFAP Purified followed by Anti-Mouse TRITC (right). Nuclei are counterstained with DAPI.
Contents: Anti-Glial Fibrillary Acid Protein (GFAP) Purified Catalog Number: 14-9892 Concentration: 0.5 mg/mL Formulation: aqueous buffer, 0.09% sodium azide, contains stabilizer if necessary Storage Conditions: Store at 2-8°C. Clone: GA5 Host/Isotype: Mouse IgG1
Product Options
Cat. No.
Size
Price
Add Qty to Cart
14-9892-80
25 ug
14-9892-82
100 ug
Note: Several countries will continue to be supplied via distributors. Country specific prices may apply.
Flow Cytometry Product Notes: Test Sizes: To accommodate multicolor flow cytometry, eBioscience is in the process of reducing test size volumes from 20 µl to 5 µl. Please check your antibody vial for the recommended test size. Fluorochrome Replacements: eBioscience is in the process of replacing all Alexa Fluor® 647 conjugated products with eFluor® 660 conjugated products.
Description
This GA5 monoclonal antibody reacts with human, mouse, rat, chicken, rabbit, and pig glial fibrillary acidic protein (GFAP). This 49-kDa type III intermediate filament protein is expressed in neural tissues and distinguishes astrocytes from other glial cells during central nervous system development. Three alternative splice variants of GFAP exist; however, α-GFAP is the predominant form expressed in astrocytes. GFAP can co-assemble with vimentin and nestin in astrocytes, but such associations are not required for assembly. Like other intermediate filaments, GFAP assembly is dependent on phosphorylation and dephosphorylation of the N-terminal domain. Studies have demonstrated that mutations in the GFAP gene lead to Alexander disease. Moreover, GFAP has also been shown to be overexpressed in certain glial-derived tumors.
Applications Reported
For research use only, not for diagnostic or therapeutic use. This GA5 antibody has been reported for use in immunoblotting (WB), immunohistochemical staining of formalin-fixed paraffin embedded tissue sections, and immunocytochemistry.
Applications Tested
This GA5 antibody has been tested by immunoblotting of lysate prepared from mouse brain and immunocytochemistry of fixed and permeabilized C6 cells. This can be used at less than or equal to 5 μg/mL.
References
Quinlan RA, Brenner M, Goldman JE, Messing A. GFAP and its role in Alexander disease. Exp Cell Res. 2007 Jun 10;313(10):2077-87.
McLendon RE, Bigner DD. Immunohistochemistry of the glial fibrillary acidic protein: basic and applied considerations. Brain Pathol. 1994 Jul;4(3):221-8.
Mokuno K, Kamholz J, Behrman T, Black C, Sessa M, Feinstein D, Lee V, Pleasure D. Neuronal modulation of Schwann cell glial fibrillary acidic protein (GFAP). J Neurosci Res. 1989 Aug;23(4):396-405. (GA5, WB)
Rasmussen S, Bock E, Warecka K, Althage G. Quantitation of glial fibrillary acidic protein in human brain tumours. Br J Cancer. 1980 Jan;41(1):113-6.
